ArticleGut microbes
A tailored series of engineered yeasts for the cell-dependent treatment of inflammatory bowel disease by rational butyrate supplementation.
Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 28 citations in OpenAlex.
- Review
- Oral probiotic delivery-based therapeutic strategies for inflammatory bowel disease.Asian journal of pharmaceutical sciences · 2026Review
- Engineering the microbiome: A novel frontier in inflammatory bowel disease treatment.Chinese medical journal · 2026Article
- Butyrate-Producing Bacteria in Intestinal Disease Therapy: Potential and Challenges.Biotechnology journal · 2026Review
- Hesperidin-loaded Eudragit S100 nanoparticles alleviate ulcerative colitis by repairing intestinal barrier and modulating gut microbiota.International journal of pharmaceutics: X · 2026Article
- Engineering probiotics as living biotherapeutics: a novel paradigm of restoring physiological barriers via targeted short-chain fatty acid delivery.Science China. Life sciences · 2026Article
- Advance Microbiota Transplantation: A Novel Addition-Subtraction Paradigm for Optimising Faecal Microbiota Transplantation.Microbial biotechnology · 2026Review
- Propionate-engineered probiotics reduce radiation-induced intestinal damage.Bioresources and bioprocessing · 2026Article
- Recent advances in the positive role ofFrontiers in immunology · 2026Review
- Functional genetic signatures of the gut microbiome in cardiometabolic diseases: mechanisms and translational opportunities.Frontiers in microbiomes · 2026Review
- Gut microbiome modulation in allergic rhinitis: from current evidence to emerging therapies.Frontiers in allergy · 2026Review
- CRISPR-Assisted Probiotic and In Situ Engineering of Gut Microbiota: A Prospect to Modification of Metabolic Disorders.Probiotics and antimicrobial proteins · 2026Review
- Microbiota-derived short-chain fatty acids in hematopoietic stem cell transplantation: immunomodulation at the host-microbiota interface.Frontiers in microbiology · 2026Review
- Current and emerging approaches to manage chronic inflammatory gut disorders.Frontiers in cellular and infection microbiology · 2026Review
- Engineering the holobiont: Synthetic biology strategies for reversing bioenergetic collapse in radiation enteritis.AIMS microbiology · 2026Review
- An Engineered Probiotic Consortium Based on Quorum-Sensing for Colorectal Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Engineered butyrate-producing yeasts mitigate Alzheimer-associated phenotypes.Signal transduction and targeted therapy · 2025Article
- Gut-directed therapeutics in inflammatory bowel disease.Current opinion in gastroenterology · 2025Review
- Exploring the gut microbiome's influence on cancer-associated anemia: Mechanisms, clinical challenges, and innovative therapies.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Skin microbiome engineering: Challenges and opportunities in skin diseases treatment.iMetaOmics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal microbiota dysbiosis and metabolic disruption are considered essential characteristics in inflammatory bowel disorders (IBD). Reasonable butyrate supplementation can help patients regulate intestinal flora structure and promote mucosal repair. Here, to restore microbiota homeostasis and butyrate levels in the patient's intestines, we modified the genome of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.